Read news on GLP-1 with our app.
Read more in the app
GLP-1 drugs linked to lower risk of serious heart-related complications and infections after surgery
NIH awards $4 million grant to study GLP-1 weight regain
Postpartum initiation of GLP-1 receptor agonists among commercially insured women in the us
Building effective multimodal care for obesity and comorbidities in the GLP-1 therapy era
Nail detachment over four times more common among GLP-1 users, first controlled study finds
Higher GLP-1 costs lead to lower adherence
‘Astonishing’ weight loss when GLP-1 drug used with second medication
How much do Americans spend on GLP-1 medications? VCU medical students measure drug affordability
Millions more people with overweight could benefit from GLP-1 drugs to protect heart health, Danish study suggests
GLP-1 receptor agonist coverage for obesity in Medicaid and total GLP-1 receptor agonist utilization
GLP-1 weight loss and diabetes drugs linked to nutritional deficiencies in nearly 1 in 6 children
GLP-1 drugs fail to help some people lose weight — scientists are on a quest for answers
Should we use GLP-1 drugs to treat obesity in children?
RNA therapy may help preserve muscle during GLP-1 weight loss
GLP-1 use among young children with obesity in US remains rare but is rising rapidly
GLP-1 treatment late in life extends lifespan in animal model
GLP-1 weight-loss medication could slow aging and extend lifespan
Can GLP-1 drugs slow ageing? Mouse study shows promise
GLP-1 meds prompt rethink of obesity and eating disorder care
